Targeted breast cancer treatment approved for routine NHS use
By Liz Wells 11 April 2025
NICE is recommending capivasertib with fulvestrant to treat women with advanced breast cancer, which means the drug will be funded immediately through the Cancer Drugs Fund.
NHS offers 'new hope' for children with severe epilepsy
By Liz Wells 20 February 2025
Hundreds of children with severe epilepsy will be able to benefit from a groundbreaking new treatment on the NHS that could significantly reduce their seizures.
Team Co-ordinator
£29,314 - £34,997 per annum
Hybrid working – allocated to offices in Coventry or York£29,314 - £34,997 per annum
Social Worker
Band G SCP 32-37 (£41,511 - £46,731 per annum)
Sandwell, West MidlandsBand G SCP 32-37 (£41,511 - £46,731 per annum)
Team Co-ordinator
£29,314 - £34,997 per annum
Hybrid working – allocated to offices in Coventry or York£29,314 - £34,997 per annum
Social Worker
Band G SCP 32-37 (£41,511 - £46,731 per annum)
Sandwell, West MidlandsBand G SCP 32-37 (£41,511 - £46,731 per annum)
©2024 Hemming Group Limited. Registered in England and Wales. Registered No: 490200. VAT number GB342 023 408
